問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2017-01-01 - 2020-10-31

Phase III

A Multicenter, Open-label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Recruiting2Sites

Terminated1Sites

Study ended1Sites

2017-03-01 - 2020-06-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

  • Condition/Disease

    Gastric Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Recruiting5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2014-08-01 - 2021-11-19

Phase III

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736

Participate Sites
6Sites

Terminated6Sites

2014-07-31 - 2014-09-30

Phase III

An open-label, randomized, multi-center, parallel grouped clinical trial comparing the efficacy and safety of Mylan's Insulin Glargine and Lantus® for patients with type 2 diabetes.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Mylan′s Insulin Glargine

Participate Sites
7Sites

Terminated7Sites

2014-05-01 - 2023-09-30

Phase II

A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736

Participate Sites
5Sites

Terminated5Sites

2014-11-11 - 2018-11-26

Phase III

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

  • Condition/Disease

    Type II Diabetes

  • Test Drug

    Canagliflozin

Participate Sites
8Sites

Terminated8Sites

2014-08-01 - 2017-12-31

Phase III

A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)

  • Condition/Disease

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
9Sites

Terminated9Sites

2014-10-01 - 2025-12-31

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER

  • Condition/Disease

    breast cancer

  • Test Drug

    Palbociclib

Participate Sites
9Sites

Terminated9Sites

2015-07-01 - 2019-10-29

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug- Experienced Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Ixekizumab(LY2439821)

Participate Sites
8Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

藍忠亮
China Medical University Hospital-Taipei

未分科

2015-08-17 - 2017-11-30

Phase III

A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily administration of TAK-438 20 mg compared to Lansoprazole 30 mg in the Treatment of Subjects with Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

侯明志
Taipei Veterans General Hospital

Digestive System Department

1 140 141 142 143 144 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB